Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Inc. (Nasdaq: SLDB), a pioneer in the field of genetic medicine, is excited to showcase its latest advancements in gene therapy for neuromuscular and cardiac disorders. The company will be presenting significant findings from its clinical trial during the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place in New Orleans.
Key Insights from the Phase 1/2 INSPIRE DUCHENNE Trial
The Phase 1/2 INSPIRE DUCHENNE trial is a crucial study focused on SGT-003, a next-generation gene therapy candidate aimed at treating Duchenne muscular dystrophy (Duchenne). This investigational therapy promises to be a game-changer for those affected by this severe genetic condition. The data reveal Solid’s innovative approaches to capsid design and therapeutic applications, demonstrating encouraging safety and efficacy results within the clinical framework.
Oral Presentations to Anticipate
Several highlights from the trial's presentations include:
Title: Initial Experience from the INSPIRE DUCHENNE Study of SGT-003 Microdystrophin Gene Therapy
Session Title: Late-Breaking Abstracts II
Date/Time: May 17, 9:15 – 9:30am CT
Presenter: Kevin Flanigan, MD
Title: Insight into the Mechanism of Action of AAV-SLB101 for Neuromuscular Indications
Session Title: AAV Gene Transfer (C): Antibody Evasion
Date/Time: May 17, 11:30 – 11:45am CT
Presenter: Jessica Boehler, PhD
Exploring Poster Presentations
In addition to oral presentations, a wealth of poster presentations will provide deeper insights into SGT-003 and related technologies:
Title: AAV-SLB101 Capsid Increases Gene Delivery in Muscle Disease Models
Date/Time: May 14, 5:30 – 7:00pm CT
Presenter: Prushti Bhavsar
Title: Full Length Transgene Quantification Utilizing Advanced Technology
Date/Time: May 13, 6:00 – 7:30pm CT
Presenter: Isabella Pajevic
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder leading to muscle degeneration and weakness. Primarily affecting boys, it manifests in early childhood, typically between the ages of three and five. The progressive nature of this illness results in significant health challenges, making the pursuit of effective therapies like SGT-003 critical.
SGT-003: A Revolutionary Approach
SGT-003 employs a meticulously designed microdystrophin construct that enhances gene delivery and muscle transduction. The proprietary capsid, AAV-SLB101, has shown significant promise in preclinical studies, indicating superior performance compared to existing therapies. Its unique design fosters improved blood flow and reduces muscle fatigue, enhancing the therapeutic prospects for individuals affected by Duchenne.
INSPIRE DUCHENNE Trial Overview
INSPIRE DUCHENNE is a pioneering study that seeks to assess the potential benefits and safety of SGT-003 in a fair trial environment, initiating the journey towards new treatment approvals. This trial is poised to attract participants from various countries, enhancing the understanding of Duchenne and the avenues available for treatment.
Solid Biosciences: Committed to Change
Solid Biosciences is focused on restoring lives through innovation in genetic medicine. Pushing boundaries, the company is dedicated to developing therapies for rare diseases, including conditions like Friedreich’s ataxia and various genetic cardiac disorders. Its diverse portfolio showcases a commitment to not just improve health outcomes but also transform the landscape of gene therapy.
For additional information or inquiries, Solid Biosciences can be reached at:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Frequently Asked Questions
What is SGT-003 and how does it work?
SGT-003 is a novel gene therapy aimed at treating Duchenne muscular dystrophy, utilizing a microdystrophin construct to improve muscle function.
When will the findings from the ASGCT be available?
Presentations from the conference will be accessible on the company's website in the Scientific Publications & Presentations section following the event.
Who are the key presenters from Solid Biosciences at the ASGCT?
Presenters include Kevin Flanigan, MD, and Jessica Boehler, PhD, who will share their insights on the latest research and findings.
What attendees can expect from the presentations?
Attendees can look forward to detailed discussions on the efficacy and safety of SGT-003 based on the INSPIRE DUCHENNE trial data.
How can Solid Biosciences improve the lives of patients?
Through dedicated research and innovation, Solid Biosciences aims to provide effective therapies that target the underlying causes of rare genetic diseases, improving quality of life.
